MARATTO

article · World Journal of Advanced Research and Reviews

Balancing the mind: The critical role of carbamazepine as a mood stabilizer in bipolar and schizoaffective disorders

2024Open accessMohamed I University

Abstract

This case study explores the therapeutic application and associated challenges of using carbamazepine as a mood stabilizer in the management of schizoaffective disorder. The patient, a 42-year-old male with a history of schizoaffective disorder, exhibited acute manic symptoms exacerbated by substance use and non-compliance with medication. The introduction of carbamazepine initially showed promise in stabilizing mood and reducing psychotic symptoms. However, the treatment course was complicated by a significant adverse dermatological reaction. This necessitated a switch to valproic acid, which was better tolerated. The case underscores the importance of careful monitoring and readiness to adjust treatment in response to carbamazepine-induced side effects. This study highlights the critical need for individualized treatment plans and emphasizes the role of pharmacogenetic testing in predicting adverse drug reactions, ensuring safer and more effective management of psychiatric conditions.

Research topics

  • Bipolar Disorder and Treatment
  • Epilepsy research and treatment
  • Pharmacological Effects and Toxicity Studies

Sustainable Development Goals

Read the original research

This page summarises published work. The authoritative version sits with the publisher.

DOI: 10.30574/wjarr.2024.22.2.1328

Is something wrong with this record? Report it or request removal.

Discussion

Discuss this research

Have you built on this work, tried to replicate it, or seen it applied in practice? Share what you know. Verified researchers and MARATTO™ domain experts can open a discussion, and any member can reply. Contributions are reviewed before they appear.

No discussion yet. Open the first thread.